3 Strong Oncology & Specialty Momentum: Beyond neuroscience, BMSs growth portfolio delivered $6.9B, led by: OPDIVO (nivolumab) US HCP: $2.5B (+8%) Breyanzi (lisocabtagene maraleucel) HCP: $359M (+58%) CAMZYOS (mavacamten) US HCP: $296M (+88%) These results reinforce BMSs transformation into a data-rich, diversified biopharma, with pivotal readouts expected in 2026 across fibrosis, multiple myeloma, and autoimmune indications
That created three problems
For instance, supplementing aged mice with NMN, which increases NAD+, improved oocyte quality and embryo blastocyst rates
Vitamin C helps recycle the body's glutathione, which can lead to a more even and radiant skin tone over time
The FDA no longer lets companies sell generic semaglutide because the shortage of name-brand drugs such as Ozempic has ended
Race-specific differences in antioxidant enzyme activity in patients with type 2 diabetes: a potential association with the risk of developing nephropathy